Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
All content for Breast Cancer Conversations is the property of SurvivingBreastCancer.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
275. Inside the VIKTORIA-1 trial with Dr. Rachel Layman
Breast Cancer Conversations
48 minutes
3 days ago
275. Inside the VIKTORIA-1 trial with Dr. Rachel Layman
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
Breast Cancer Conversations
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
